Patrick Daly

DocwireNews

In the BladderPath study, researchers explored staging suspected muscle-invasive bladder cancer (MIBC) with MRI and biopsy instead of conventional transurethral resection of bladder tumor (TURBT). Presenting at the <a href="https://www.esmo.org/meetings/esmo-congress-2022">ESMO Congress 2022</a>, the study&rsquo;s lead author, Nicholas James, reported that the randomized trial enrolled 143 patients (median years of age, 74) between May 2018 and December 2021.Among the participants, 47.9% had probable non-muscle-invasive bladder cancer (NMIBC), and 52.1% had possible MIBC. Patients with suspected MIBC were randomized to assessment via standard TURBT or MRI and biopsy. All patients with probable NMIBC underwent TURBT.<h3>MRI-Alternative to TURBT Yields Superior Time to Correct Treatment</h3>In an initial feasibility phase, the primary end point was the proportion of patients who completed the allocated assessment, with a target of 80%. In the following efficacy phase, the primary measure was the time to correct treatment&mdash;TURBT for NMIBC or the first of chemotherapy, radiotherapy, surgery, or elective palliative care for MIBC&mdash;with a target of 30-day reduction in time to correct treatment.During the feasibility phase, 95% of patients with MIBC completed their allocated assessment (37 of 39; 95% CI, 83-99%), James noted. In the efficacy phase, TURBT demonstrated a median time to correct MIBC treatment of 98 days (95% CI, 72-174) compared with 53 days (95% CI, 20-89) with MRI plus biopsy (hazard ratio [HR], 3.4; 95% CI, 1.4-8.3; P=.0046). Additionally, TURBT and MRI-based assessments among all patients led to a median time to correct treatment of 37 and 31 days, respectively (HR, 1.3; 95% CI, 0.9-1.8).James summarized that &ldquo;an MRI-directed pathway led to substantial shortening of time to correct treatment for MIBC patients with no detrimental effect of time to treatment for NMIBC patients.&rdquo;View More Cancer <a href="https://www.docwirenews.com/esmo-2022/">Research Featured at the ESMO Congress 2022</a>

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

MRI Plus Biopsy as an Alternative to TURBT in Bladder Cancer Staging

Oncology

In the BladderPath study, researchers explored staging suspected muscle-invasive bladder cancer (MIBC) with MRI and biopsy instead of conventional transurethral resection of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe